

PARAGON-HF TRIAL



AMERICAN
COLLEGE of
CARDIOLOGY

Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction

Multicenter, randomized, double-blind clinical trial



Objective: To assess the role of angiotensin-nepriylsin inhibitors in patients with heart failure with preserved ejection fraction (HFpEF).

4,822
patients

Inclusion criteria: patients with HF (NYHA class II-IV), ejection fraction $\geq 45\%$, elevated natriuretic peptides and structural heart disease were included.



Sacubitril-valsartan
(n=2,407)

VS

Valsartan
(n=2,389)



PRIMARY OUTCOME

37.1

Composite of HF hospitalizations and CV mortality %

RR 0.87; 95% CI, 0.75 to 1.01, P = 0.06

42.2

SECONDARY OUTCOME

1.4

Composite of renal failure, ESRD or worsening GFR %

HR 0.50; 95% CI, 0.33 to 0.77

2.7

14.2

All-cause mortality %

HR 0.97; 95% CI, 0.84 to 1.13

14.6

Conclusion: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for HF and death from CV causes among patients with HFpEF (EF $\geq 45\%$).